FLLL32, a novel curcumin analogue, is a potent STAT3 inhibitor. FLLL32 specifically reduced STAT3 phosphorylation at Tyr705 (pSTAT3) and induced apoptosis at micromolar amounts in human melanoma cell lines and primary melanoma cultures. FLLL32 promoted loss of cell proliferation at lower concentrations than curcumin leading to caspase-3- dependent apoptosis. FLLL32 may have potential for targeting multiple myeloma, glioblastoma, liver cancer, and colorectal cancer cells expressing constitutive STAT3 signaling.
JAK Inhibitors Related Products:
Ruxolitinib; Ruxolitinib phosphate; Tofacitinib; AZD1480; Momelotinib; Gandotinib; AZ960; Pacritinib; XL019; Upadacitinib; Decernotinib; Filgotinib; GLPG0634 analogue; AG-490 (Tyrphostin B42); NSC-42834; Itacitinib; Go6976; Baricitinib; Oclacitinib; Oclacitinib maleate; WP1066